Taysha Gene Therapies (TSHA) Projected to Post Earnings on Wednesday

Taysha Gene Therapies (NASDAQ:TSHA) is expected to announce its earnings results before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $2.05 million for the quarter.

Taysha Gene Therapies Price Performance

Taysha Gene Therapies stock opened at $1.64 on Friday. The business’s 50-day simple moving average is $1.71 and its 200 day simple moving average is $2.00. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48. The stock has a market cap of $336.11 million, a price-to-earnings ratio of 2.60 and a beta of 0.92. Taysha Gene Therapies has a 12-month low of $1.19 and a 12-month high of $4.32.

Wall Street Analyst Weigh In

Several research firms have weighed in on TSHA. JMP Securities reiterated a “market outperform” rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Canaccord Genuity Group raised their price objective on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Needham & Company LLC reissued a “buy” rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a research note on Monday, January 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Finally, Chardan Capital reiterated a “buy” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, November 14th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Taysha Gene Therapies currently has an average rating of “Buy” and an average target price of $6.63.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.